Haematologic malignancies
Clinical research activity includes diffuse large B-cell lymphoma and related aggressive B-cell lymphoma subtypes, with interest in both standard and biologically defined entities such as primary cutaneous DLBCL, intravascular large B-cell lymphoma, EBV-positive DLBCL, and high-grade B-cell lymphoma.
- Diffuse large B-cell lymphoma
- Primary cutaneous lymphoma
- High-grade B-cell lymphoma
Additional focus extends to rarer lymphoma presentations, including primary mediastinal large B-cell lymphoma, follicular lymphoma grade 3B, and T-cell/histiocyte-rich large B-cell lymphoma.
Head and neck cancer
Trials address locally advanced and locoregionally recurrent head and neck squamous cell carcinoma, with emphasis on disease control after radiochemotherapy and in settings where recurrence limits treatment options.
- Head and neck squamous cell carcinoma
- Locoregional recurrence
- Radiochemotherapy
Research interest also includes PD-L1-positive disease, reflecting attention to immunologically selected patient populations in head and neck oncology.
Prostate cancer
One area of investigation concerns locally advanced high-risk prostate cancer, with a specific focus on patients being assessed for operability after neoadjuvant hormonal and androgen-targeted treatment.
- High-risk prostate cancer
- Locally advanced disease
- Operability assessment
This reflects interest in preoperative management and surgical decision-making in advanced urologic oncology.
Small cell lung cancer
Research includes extensive-stage small cell lung cancer, with attention to combined thoracic radiotherapy, systemic treatment, and consolidation strategies in advanced thoracic malignancy.
- Extensive-stage small cell lung cancer
- Thoracic radiotherapy
- Consolidation treatment
The trial portfolio shows interest in integrating immunotherapy with multimodal treatment for aggressive lung cancer.
